BGM Group Ltd. BGM
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.18
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.9M | $25.1M | $46.5M | $64.9M | $57.1M | $50.0M | $46.1M | $50.4M | — |
| Cost of revenue | $31.6M | $21.0M | $44.7M | $58.6M | $51.5M | $42.5M | $36.4M | $42.2M | — |
| Gross profit | $6.3M | $4.1M | $1.8M | $6.2M | $5.6M | $7.5M | $9.7M | $8.1M | — |
| R&D | $672.7K | $1.4M | $568.5K | $1.2M | $8.0K | $54.0K | $44.0K | — | — |
| SG&A | $18.2M | $3.3M | $3.8M | $2.1M | $2.3M | $2.7M | $3.5M | $2.2M | — |
| Operating income | -$12.6M | -$563.8K | -$2.6M | $2.1M | $2.4M | $4.8M | $6.2M | $6.0M | — |
| Interest expense | — | — | $99.2K | $24.9K | $57.7K | $242.9K | $223.7K | $216.2K | — |
| Pre-tax income | -$19.9M | -$2.1M | -$7.9M | $1.6M | $3.4M | $5.8M | $6.9M | $6.1M | — |
| Income tax | $277.8K | $620.0K | $219.2K | $194.3K | $255.1K | $864.9K | $1.0M | $943.4K | — |
| Net income | -$19.9M | -$1.4M | -$7.8M | $1.1M | $3.2M | $5.1M | $5.9M | $5.2M | — |
| EPS, basic | -0.18 | -0.20 | -1.08 | 0.15 | 0.09 | 0.17 | 0.18 | — | — |
| EPS, diluted | -0.18 | -0.20 | -1.08 | 0.15 | 0.09 | 0.17 | 0.18 | 0.17 | — |
| Shares, diluted (wtd. avg.) | 113.3M | 7.2M | 7.2M | 7.2M | 34.1M | 30.0M | 30.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.8M | $9.8M | $7.5M | $15.0M | $12.6M | $11.9M | $4.6M | $5.6M | $5.9M |
| Short-term investments | — | — | $1.0M | — | — | — | — | — | — |
| Receivables | $4.3M | $1.5M | $2.0M | $815.3K | $1.7M | $1.1M | $603.8K | — | — |
| Inventory | $20.1M | $5.0M | $5.0M | $8.9M | $12.5M | $12.0M | $12.5M | — | — |
| Total current assets | $51.5M | $29.8M | $34.5M | $30.0M | $40.4M | $37.5M | $25.0M | — | — |
| Property, plant and equipment | — | — | — | $10.2M | $9.1M | $7.4M | $7.7M | — | — |
| Goodwill | $350.8M | — | — | — | — | — | — | — | — |
| Other intangibles | $4.5M | $4.5M | $3.4M | $1.7M | $1.9M | $1.9M | $1.8M | — | — |
| Total assets | $433.8M | $53.0M | $51.3M | $64.5M | $75.4M | $48.1M | $35.3M | — | — |
| Accounts payable | $6.6M | $4.1M | $3.6M | $5.3M | $6.6M | $4.4M | $3.6M | — | — |
| Total current liabilities | $41.6M | $8.8M | $6.7M | $9.2M | $18.2M | $18.4M | $11.7M | — | — |
| Total liabilities | $41.9M | $8.9M | $6.9M | $9.6M | $18.7M | $19.3M | $12.6M | — | — |
| Retained earnings | -$15.8M | $4.3M | $5.9M | $15.5M | $14.7M | $12.2M | $7.6M | — | — |
| Total equity | $390.9M | $42.7M | $44.4M | $55.0M | $56.7M | $28.8M | $22.6M | $17.7M | $13.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.4M | $544.2K | $312.2K | $12.7M | $345.0K | $5.1M | -$580.2K | $4.4M | — |
| Depreciation and amortisation | $1.5M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M | $1.2M | $1.3M | — |
| Stock-based compensation | $10.2M | — | — | $20.0K | — | — | — | — | — |
| Capital expenditure | $1.6M | $240.1K | $179.8K | $2.0M | $1.5M | $449.8K | $616.4K | $1.1M | — |
| Investing cash flow | -$162.9K | $983.4K | -$4.7M | -$3.3M | -$24.2M | -$375.6K | -$800.2K | -$1.4M | — |
| Financing cash flow | $2.6M | -$491.7K | -$2.9M | -$5.9M | $24.0M | $2.1M | $507.2K | -$3.1M | — |
| Dividends paid | — | — | $1.8M | — | — | — | — | $733.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-085247.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $50.4M | $46.1M | $50.0M | $57.1M | $64.9M | $46.5M | $25.1M | $37.9M |
| Gross profit | — | $8.1M | $9.7M | $7.5M | $5.6M | $6.2M | $1.8M | $4.1M | $6.3M |
| Net income | — | $5.2M | $5.9M | $5.1M | $3.2M | $1.1M | -$7.8M | -$1.4M | -$19.9M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |